DeCamillis Rebekah B, Hekman Aliza L, Priest David H
Novant Health, Infectious Diseases, Winston-Salem, NC.
Clin Liver Dis (Hoboken). 2024 Jan 25;23(1):e0118. doi: 10.1097/CLD.0000000000000118. eCollection 2024 Jan-Jun.
Screening patients with opioid use disorder (OUD) for HCV can potentially decrease morbidity and mortality if HCV-infected individuals are linked to care. We describe a quality improvement initiative focused on patients with OUD, incorporating an electronic health record decision-support tool for HCV screening across multiple health care venues, and examining the linkage to HCV care. Of 5829 patients with OUD, 4631 were tested for HCV (79.4%), (compared to a baseline of 8%) and 1614 (27.7%) tested positive. Two hundred and thirty patients had died at the study onset. Patients tested in the acute care and emergency department settings were more likely to test positive than those in the ambulatory setting (OR = 2.21 and 2.49, < 0.001). Before patient outreach, 279 (18.2%) HCV-positive patients were linked to care. After patient outreach, 326 (23.0%) total patients were linked to care. Secondary end points included mortality and the number of patients who were HCV-positive who achieved a cure. The mortality rate in patients who were HCV-positive (12.2%) was higher than that in patients who were HCV-negative (7.4%) (OR = 1.72, < 0.001) or untested patients (6.2%) (OR = 2.10, <0.001). Of the 326 with successful linkage to care, 113 (34.7%) had a documented cure. An additional 55 (16.9%) patients had a possible cure, defined as direct acting antiviral ordered but no follow-up documented, known treatment in the absence of documented sustained viral response lab draw, or documentation of cure noted in outside medical records but unavailable laboratory results. A strategy utilizing electronic health record decision-support tools for testing patients with OUD for HCV was highly effective; however, linking patients with HCV to care was less successful.
如果感染丙型肝炎病毒(HCV)的个体能够获得治疗,那么对患有阿片类药物使用障碍(OUD)的患者进行HCV筛查可能会降低发病率和死亡率。我们描述了一项针对OUD患者的质量改进计划,该计划纳入了一个电子健康记录决策支持工具,用于在多个医疗场所进行HCV筛查,并检查与HCV治疗的联系。在5829例OUD患者中,4631例接受了HCV检测(79.4%)(相比基线的8%),1614例(27.7%)检测呈阳性。230例患者在研究开始时已经死亡。在急性护理和急诊科接受检测的患者比在门诊接受检测的患者更有可能呈阳性(比值比分别为2.21和2.49,P<0.001)。在患者外展服务之前,279例(18.2%)HCV阳性患者获得了治疗。患者外展服务之后,共有326例(23.0%)患者获得了治疗。次要终点包括死亡率以及HCV阳性且治愈的患者数量。HCV阳性患者的死亡率(12.2%)高于HCV阴性患者(7.4%)(比值比= =1.72,P<0.001)或未接受检测的患者(6.2%)(比值比=2.10,P<0.001)。在326例成功获得治疗的患者中,113例(34.7%)有治愈记录。另外55例(16.9%)患者可能已治愈,定义为已开具直接作用抗病毒药物但无后续记录、在无记录的持续病毒反应实验室检测情况下已知接受治疗,或外部医疗记录中有治愈记录但实验室结果不可用。利用电子健康记录决策支持工具对OUD患者进行HCV检测的策略非常有效;然而,将HCV患者与治疗联系起来的成功率较低。